Challenges and Threats due to Deadly Corona Virus in India and Dealing it with Social Vaccine (distancing) - the Only Weapon
Abstract
The whole world is, presently, reeling under a serious crisis due to wide spread of a very unique and deadly corona virus. It is said to have originated from China and spread over more than 200 countries across the world. There have been reports of high mortality and morbidity in China, Spain, Italy, USA, UK and France due to wide spread of this dangerous and contagious disease. Unfortunately, this war is being fought by the frontline warriors i.e. doctors, nurses, health workers, sanitary staff but, with no real weapon presently, as no drug or vaccine has been found effective to deal with this deadly virus. The spread/ transmission cycle is very fast due to its very highly contagious nature and fast multiplication. Though, India has made all concerted efforts from the very beginning with all proactive actions and preparedness to deal with the situation due to coronavirus, yet it is becoming a Challenging task in some hotspots due to lack of social distancing or lockdown by some people in the community. The first phase of lockdown in the whole country started on 25th March for 21 days in order to break down the chain of transmission. However, due to its spread in some hotspots, it has been extended for another 19 days so as to well control the clusters and to prevent further spread. In an address to the Nation, Dr. Harsh Vardhan, Hon. Health Minister of India stressed the need of social distancing and lockdown as comprehensive strategy for prevention and break the chain of transmission for coronavirus and term social distancing as “social vaccine†besides other measures being taken for diagnosis and treatment. An attempt has been made in this manuscript to describe the challenges and threats caused by deadly corona virus in India with the benefits of social vaccine (distancing)-the only weapon to prevent and break the transmission.
How to cite this article:
Sharma SN, Singh SK. Challenges and Threats due to Deadly Corona Virus in India and Dealing it with Social Vaccine (distancing) - the Only Weapon. J Commun Dis 2020; 52(1): 7-13.
DOI: https://doi.org/10.24321/0019.5138.202002
References
WHO: COVID-19 Strategy Update. Pp 1-15.
Banerjee A, Kulcsar K, Misra V, Frieman M. Mossman K Bats and coronaviruses. Viruses 2019; 11. E41.
Plowright RK, Eby P, Hudson PJ, Smith IL, Westcott D, Bryden WL et al. Ecological dynamics of emerging bat
virus spillover. Proc Biol Sci 2015; 282: 20142124.
Pragya D. Yadav et. Al. 2020 : Detection of coronaviruses in Pteropus & Rousettus species of bats from different States of India. Indian J Med Res, Epub ahead of print DOI: 10.4103/ijmr.IJMR_795_20.
Statement on the meeting of the International Health Regulations (2005) Emergency Committee regarding
the outbreak of novel coronavirus (2019-nCoV) - WHO, January 23, 2020.
Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China,
from 2019 to 2020: A data-driven analysis in the early phase of the outbreak - Jan. 30, 2020.
Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic prediction -
Jonathan M. Read et al, Jan. 23,2020.
Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China - Maimuna Majumder and Kenneth
D. Mandl, Harvard University - Computational Health Informatics Program - Posted: 24 Jan 2020 Last revised:
Jan 2020.
Report 3: Transmissibility of 2019-nCoV - 25 January 2020 - Imperial College London.
16Who: “Live from Geneva on the new #coronavirus outbreakâ€.
A novel coronavirus outbreak of global health concern - Chen Want et al. The Lancet January 24, 2020.
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia inWuhan, China - Wang et. al, JAMA, Feb. 7, 2020.
WHO: Advice on the use of point-of-care immunodiagnostic tests for COVID-19. Scientific brief
April 2020. 1-3.
Bruning AHL, Leeflang MMG, Vos JMBW, Spijker R, de Jong MD, Wolthers KC et al. Rapid Tests for Influenza,
Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review and Meta-analysis. Clin
Infect Dis [Internet]. 2017 Sep 15 [cited 2020 Apr 1]; 65(6): 1026-1032.
Liu Y, Liu Y, Diao B, Ren Feifei et al. Diagnostic indexes of a rapid IgG/IgM combined antibody test for SARSCoV2.medxriv [Internet]. 2020; Available from: https://doi.org/10.1101/2020.03.26.20044883.
Zhang P, Gao Q, Wang T, Ke Y et al. Evaluation of recombinant nucleocapsid and spice protein
serological diagnosis of novel coronavirus disease 2019 (COVID-19). medxriv [Internet].
; Available from: https://www.medrxiv.org/content/10.1101/2020.03.17.20036954v1.
Pan Y, Li X, Yang G, Fan J et al. Serological immunochromatographic approach in diagnosis
with SARS-CoV-2 infected COVID-19 patients. medxriv [Internet]. 2020; Available from: https://doi.
org/10.1101/2020.03.13.20035428 .
Li Z, Yi Y, Luo X, Xion N, et al. Development and clinical application of a rapid IgM-IgG combined antibody
test for SARS-CoV-2 infection diagnosis. Journal of medical virology. https://onlinelibrary.wiley.com/doi/
abs/10.1002/jmv.25727.
ICMR: Advisory on feasibility of using pooled samples for molecular testing of COVID-19. Uploaded on
website.
Caly L, Druc DJ, Catton MG, Jans DA, Wagstaff KM. The FDA - approved drug Ivermectine inhibits the
replication of SARS-CoV-2 in vitro. Antiviral Research (Accepted : 29.3.2020).
Singh SK, Jain SK, Sharma SN. Prevention and Control of COVID-19 in Indian Perspective. Epidemiology
International 2020: 5(1): 32-38.
Copyright (c) 2020 Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
